'''pomaglumetad Methionil'''（
该药物是pomaglumetad（LY-404039）的非活性前药，它充当高度结合的选择性|选择性代谢型谷氨酸MGLU 2 2 和mglu 3 3 3 3 受体受体。 was found to be low in humans, pomaglumetad methionil has an estimated oral bioavailability of approximately 49%. The drug is active transport|transported by the peptide transporter 1 (PepT1), resulting in it being rapidly and efficiently absorption (pharmacokinetics)|absorbed, and is then hydrolysis|hydrolyzed into pomaglumetad。消除pomaglumetad甲基二尼尔的半衰期为1.5至2.4
Pomaglumetad Methionil正在Eli Lilly and Company，Denovo Biopharma和其他机构进行开发。
==另请参见==
* pomaglumetad＃pomaglumetad Methionil |pomaglumetad§pomaglumetadMethionil
'''pomaglumetad Methionil'''（ 该药物是pomaglumetad（LY-404039）的非活性前药，它充当高度结合的选择性|选择性代谢型谷氨酸MGLU 2 2 和mglu 3 3 3 3 受体受体。 was found to be low in humans, pomaglumetad methionil has an estimated oral bioavailability of approximately 49%. The drug is active transport|transported by the peptide transporter 1 (PepT1), resulting in it being rapidly and efficiently absorption (pharmacokinetics)|absorbed, and is then hydrolysis|hydrolyzed into pomaglumetad。消除pomaglumetad甲基二尼尔的半衰期为1.5至2.4 Pomaglumetad Methionil正在Eli Lilly and Company，Denovo Biopharma和其他机构进行开发。 ==另请参见== * pomaglumetad＃pomaglumetad Methionil |pomaglumetad§pomaglumetadMethionil
Mobile version